华熙生物(688363) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was approximately RMB 4.22 billion, a decrease of 21.49% compared to the previous year[2] - Net profit attributable to shareholders of the parent company reached approximately RMB 291.07 million, an increase of 67.03% year-on-year[2] - The basic earnings per share increased to RMB 0.61, reflecting a growth of 69.44% compared to the previous year[2] Assets and Equity - Total assets at the end of the reporting period were approximately RMB 8.66 billion, a slight decrease of 0.02% from the beginning of the period[3] - Shareholders' equity attributable to the parent company increased by 4.02% to approximately RMB 7.08 billion[3] Cost Management - The company implemented structural optimization in its core business areas, leading to a reduction in sales expenses by over 30%[6] - Management expenses decreased by over 10% year-on-year, contributing to profit growth[6] Research and Development - The company focused on research in cell biology and glycoscience, enhancing its ability to industrialize bioactive substances and regenerative materials[7] Operational Efficiency - The application of digital and AI technologies in operations is expected to improve overall operational efficiency[7] - The company aims to transition from "scale expansion" to "quality growth" through systematic organizational optimization[7]